Eagle Pharmaceuticals ($EGRX) Investor Settlement

The parties have reached an agreement to settle the case, but the terms are still being finalized. You can submit your application now, and it will be processed once claims filing opens.

D. New Jersey

Court

2:23-cv-23011

Case number

08/09/2022

Class period Start

10/01/2024

Class period End

Eagle Pharmaceuticals has agreed to a settlement with $EGRX investors to resolve claims that it misled them about product performance and financial controls related to its cancer drug PEMFEXY.

Outline:

Eagle promoted PEMFEXY as a strong revenue driver and highlighted continued demand for the product. Investors later alleged the company failed to disclose slowing sales caused by excess and expired inventory at a key wholesale customer. When Eagle restated revenue tied to these issues, the stock fell. Investors filed suit, and the parties later reached a tentative settlement.

Timeline:
August 8, 2022: Eagle filed its Q2 report, stating it expected continued pull-through for PEMFEXY.
November 2022–February 2023: The company highlighted PEMFEXY revenue while allegedly failing to disclose inventory issues.
May 2023: Eagle restated revenue figures due to expired inventory tied to a key wholesale customer.
Mid 2023: $EGRX declined as more details about the issue emerged.
December 2023: Investors filed suit. 
October 2025: The parties reached a tentative settlement.
Background:

Eagle Pharmaceuticals marketed its chemotherapy drug PEMFEXY as an important contributor to the company’s revenue growth. During earnings calls and public filings, the company emphasized strong demand and ongoing product uptake.

Investors later alleged that a key wholesale customer was experiencing excess inventory and product expiration, which slowed the expected pull-through of PEMFEXY. According to the complaint, Eagle did not disclose these issues while continuing to report strong revenue tied to the product.

In May 2023, Eagle restated revenue figures after identifying problems tied to expired inventory held by a wholesale customer. The company also faced questions about the effectiveness of its financial reporting controls.

Following these disclosures, $EGRX declined as investors reassessed the company’s financial performance and product outlook. Shareholders alleged Eagle’s earlier statements about PEMFEXY demand and revenue lacked a reasonable basis and misled the market.

What Can Investors Expect Now?

Eagle Pharmaceuticals has agreed to a settlement with $EGRX investors to resolve claims tied to disclosures about PEMFEXY sales performance and related financial reporting controls.

If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section.

Case Type

US Securities Class Action

Case Status

Tentative Settlement

Alleged Offence

Misleading Statements,

Financial Misrepresentation,

Failure to Disclose,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Filing date

12/11/2023

Lead Plaintiff Deadline

02/09/2024

Plaintiffs

Nicholas Miller

Attorneys

Carella Byrne Cecchi Brody & Agnello, Glancy Prongay & Murray

Defendants

Brian Cahill, Scott Tariff

Judge

Susan D Wigenton

Trades matching type

FIFO

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.